



Investor presentation 3Q 2020.



November 2020

Disclaimer.



This presentation (the “Presentation”) was prepared by MEDICALgorithmics SA (the “Company”) with due care; however, it may contain certain inconsistencies or omissions. The Presentation does not contain a complete or thorough financial analysis of the Company and does not present its standing or prospects in a comprehensive or in-depth manner. Therefore, anyone who intends to make an investment decision with respect to the Company should rely on information disclosed in the official filings of the Company, published in accordance with the laws applicable to the Company. This Presentation was prepared for information purposes only and does not constitute an offer to buy or to sell any financial instruments.

The Presentation may contain 'forward-looking statements'. However, such statements should not be treated as assurances, forecast or projections of expected future results of the Company. Any statements concerning expectations of future financial results should not be understood as guarantees that such results will actually be achieved in future. The expectations of the Management Board are based on their current knowledge and depend on many factors from which the actual results achieved by the Company may differ materially from the results presented in this document. Many of these factors are beyond the awareness and control of the Company or the Company’s ability to foresee them. The Presentation and forward-looking statements were based solely on the information at hand on the date the Presentation was prepared.

Neither the Company, nor its directors, officers, advisors, nor representatives of any such persons are liable on account of any reason resulting from the use of this Presentation. Additionally, no information contained in this Presentation constitutes any representation or warranty of the Company, its officers or directors, advisors or representatives of any of the above persons.

All rights reserved © MEDICALGORITHMICS S.A. 2020

Presentation Plan.



| Financial Results 3Q20

Group Development

Innovation Roadmap


Q&A

Revenue.

- Number of claims increased by 25% Q/Q and 6% Y/Y as a result of rebound after 2Q20 COVID crush, and implemented business improvements
- Average reimbursement rates paid by insurers (in USD) were stable in 3Q20 vs 2Q20 and lower Y/Y due to changes in business model
- Out of US revenues down by 15% Q/Q (services up 13% Q/Q, devices sales down by 51% Q/Q)
- FX impact amounts to -1.8 M PLN in 3Q20 Q/Q


Revenue M PLN

+9% q/q



Claims submitted to insurers '000


+25% q/q



Operating Costs.

- Total operating costs grew by 2.1 M PLN Q/Q in 3Q20 (+6% Q/Q) and decreased by 17.8 M PLN Y/Y in 9M2020 (-14% Y/Y)
- Employee benefits up by 1.4 M PLN Q/Q in 3Q20 (+7% Q/Q) due to:
 - Increase in Medi-Lynx related to higher number of test (+23% FTE Q/Q)
 - Increase in Medicalgorithmics related to turn back to full time (+0.7 M PLN)
 - FX impact (+1.5 M PLN) in 3Q20

Operating costs 3Q20



M PLN	3Q 20	2Q 20	q/q	3Q 19
Employee benefits	21.4	20.0	1.4	27.2
Third party service	7.3	7.6	(0.3)	8.4
Depreciation	3.8	4.1	(0.3)	5.1
Raw material consumption	2.1	1.2	0.9	1.9
Other costs	0.8	0.7	0.1	1.6
Total operating costs	35.5	33.4	2.1	44.3

Financial Results.

- Revenue increased by 2.0 M PLN Q/Q due to higher number of claims, and stable average rate for test, with negative fx impact
- Operating costs higher Q/Q mainly due to slight increase of employee cost and increase in raw materials due to low base effect in expenses for service repairs and replacement of hardware in MediLynx
- Operating result down by 4.4M PLN Q/Q mainly to one-off (1.0 M USD) of non-refundable CARES Act support for healthcare sector companies in base quarter

M PLN	3Q 20	2Q 20	Q/Q	1Q 20
Sales revenue	25.1	23.1	2.0	36.1
Total costs of sales	(35.5)	(33.4)	2.1	(44.6)
Profit/(loss) on sales	(10.3)	(10.3)	0	(8.6)
Net other operating	(0.1)	4.2	(4.3)	(0.1)
EBIT	(10.5)	(6.1)	(4.4)	(8.6)
Net finance	(0.8)	(1.0)	0.2	0.5
Profit/(loss) before tax	(11.3)	(7.2)	(3.1)	(8.1)
Income tax	3.7	2.7	1.0	1.1
Net profit/(loss)	(7.5)	(4.5)	(3.0)	(6.9)
Net profit/(loss) attributable to Shareholders of the Parent Company	(3.4)	(1.2)	(2.2)	(3.3)
EBITDA	(6.7)	(2.1)	(4.6)	(4.6)

Cash & debt.

- Cash position was 32.7M PLN at the end of the 3Q20 with net debt at 14.3 M PLN
- Terms of repayment of promissory note are a subject of negotiations

M PLN	September 30, 2020
Promissory note	8.2
Cares Act loan	12.4
Bank debt	10.5
Total financial debt	31.0
Lease liabilities	16.0
Total financial liabilities	47.0
Cash and term deposits	32.7
Net financial debt (before IFRS 16)	-1.7
Net debt	14.3

Debt ratio 0.3x

Presentation Plan.



Financial Results 3Q20

| Group Development

Innovation Roadmap

Q&A

USA Operations Continuing During Covid-19 Pandemic.


- Daily sessions are back to Pre-Covid level in the 320+ a day. In-Network and test mix are being focused on for improvement
- Many states are still in lock down mode, increase positive testing. Political environment fueling the situation - cautiously optimistic
- Productivity programs are on track for the 7M of improvement, Introducing global Six Sigma Lean program with Master BB
- Working remote is the “New Norm” and showing continuing productivity with specifics metrics and guidelines for employee expectations
- Forecast for 2020 is on track, 2021 business plan is being built with new product Introductions, productivity improvements and FTE requirement

**Global company collaboration, accountability and commitment to future success,
Is driving the new exciting culture ...**


Significant improvement in sessions started.

- Changes in # of sessions
summary: Current 4 weeks vs previous 4 week: -8% ; Current 12 weeks vs previous 12 weeks: +25%
- Average numbers of claims per working day and sessions started are simmiliar to pre-pandemic period
- 8208 claims reported in October, (+67% vs April 2020)
- 391 claims per working day in October (+75% vs April 2020; +24% Y/Y)

MediLynx: Sessions started (weekly, 4 weeks moving average)



MediLynx: Average # of daily claims




Commercialization Imperatives post Covid.

In November MediLynx inked an agreement with new significant payor. Approximately 85 percent of the population is covered for Medi-Lynx's arrhythmia diagnostics services with "in-network" model.

Last 4 months are demonstrating signs of recovery

- Managing accounts to drive profitability
- Driving the clinical efficacy of MCT ,
- Process: targeted selling for profitable growth
- Leverage in-network expansion
- Impactful Patch launch
- Focus on New account development



***Global Theme is driving profitable Growth
in an Enterprise / IDN and INN model***

Business out of US.

More than 300 new devices sold in 3Q20


Shift for telehealth services supporting for business growth

Company expects to reach sales targets for FY2020 despite Covid impact


Medicalgorithmics Out of US revenues from services up 13% Q/Q, from devices sales down by 51% Q/Q

Agreement signed in Austria

Medicalgorithmics: Active devices out of US



Medicalgorithmics: Revenues out of US (kPLN)



Presentation Plan.



Financial Results 3Q20

Group Development

| Innovation Roadmap

Q&A

Innovation roadmap – Extended Holter.

Addition of Extended Holter

Status: Complete - launched in 1Q20
Currently 5% - 10% of all sessions
Positive impact on the services mix

- All-in-1 device = easy management of inventory & software systems
- Can transition from **Holter to Event** or from **Holter to Telemetry** seamlessly, when the patient is at home (without patient interaction, no need to hook up new device)
- Streamlined enrollment process with **pre-programmed insurance requirement** and indication which monitor type is applicable
- Multi-language interface for the device, making the patient training process easy
- **Digital workflow** for reviewing the reports including digital signature, automatic downloading and printing



Innovation roadmap – Pocket ECG IV, PatchECG & AI.

PocketECG IV

Status: on track - FDA & Telecom approved – delivery at the end of 2020

- Utilizes **LTE technology** allowing to more efficiently live-stream continuous ECG with all heartbeat labels, patient's symptoms and activity information

Deep Learning AI v 2.0 (DeepRhythmAI 2.0)

Status: on track - ready for FDA submission, approval est for Q2.21/Q3.21

- Further automating the ECG approval process
- full automation est. for 2021/2022

NextGen PocketECG software platform

Status: on track – est. for Q3.21/Q4.21

- Fully web-based software solution
- Based on the AI 2.0 engine
- limited interactivity for the ECG techs due to automation
- Support for mobile platforms / improved access to granular data

PatchECG

Status: on track - certification started – launch date: Apr 15, 2020

- Easy to use **wearable patch**
- Single ECG channel
- Device complementary to the PocketECG system
- Utilizes internally developed cutting edge technology to access & analyze ECG signal



Presentation Plan.



Financial Results 3Q20

Group Development

Innovation Roadmap

| Q&A



Medicalgorithmics SA
Central Tower, 19 piętro
Al. Jerozolimskie 81
02-001 Warszawa
www.medicalgorithmics.pl



Contact IR
CC Group
Piotr Owdziej
+48 697 612 913
piotr.owdziej@ccgroup.pl



Contact PR
CC Group
Katarzyna Sadowska
+48 697 613 020
katarzyna.sadowska@ccgroup.pl

